Search

Your search keyword '"Clinical Trials, Phase II as Topic economics"' showing total 12 results
Start Over Descriptor "Clinical Trials, Phase II as Topic economics" Publication Type Magazines
12 results on '"Clinical Trials, Phase II as Topic economics"'

1. Simple Models and Ice Bucket Challenge Fuel Progress in ALS Treatment.

Author

Kuehn BM

Subjects
Animals, Caenorhabditis elegans physiology, Clinical Trials, Phase II as Topic economics, Disease Models, Animal, Humans, Neuromuscular Junction drug effects, Amyotrophic Lateral Sclerosis drug therapy, Antipsychotic Agents therapeutic use, Fund Raising methods, Pimozide therapeutic use, Research Support as Topic, Social Media
Published
2018
Full Text
View/download PDF

3. Deal watch: AbbVie invests in pioneering celiac disease therapy.

Author

Crunkhorn S

Subjects
Celiac Disease immunology, Clinical Trials, Phase II as Topic economics, Clinical Trials, Phase III as Topic economics, Drug Industry trends, Humans, Peptide Hydrolases adverse effects, Peptide Hydrolases economics, Peptide Hydrolases pharmacology, United States, Celiac Disease drug therapy, Drug Design, Drug Industry economics, Investments, Peptide Hydrolases therapeutic use
Published
2013
Full Text
View/download PDF

5. Market watch: upcoming market catalysts in Q4 2012.

Author

Tucker J

Subjects
Antineoplastic Agents economics, Antineoplastic Agents therapeutic use, Antiviral Agents economics, Antiviral Agents therapeutic use, Clinical Trials, Phase II as Topic economics, Clinical Trials, Phase II as Topic trends, Health Care Sector trends, Humans, United States, Drug Approval economics, Health Care Sector economics
Published
2012
Full Text
View/download PDF

6. Amgen swallows Micromet to BiTE into ALL market.

Author

Sheridan C

Subjects
Antibodies, Bispecific therapeutic use, Clinical Trials, Phase II as Topic economics, Drug Industry economics, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Antibodies, Bispecific economics, Immunotherapy economics, Precursor Cell Lymphoblastic Leukemia-Lymphoma economics
Published
2012
Full Text
View/download PDF

7. Time for reform in the drug-development process.

Author

Fricker J

Subjects
Bayes Theorem, Benzamides, Clinical Trials, Phase I as Topic economics, Clinical Trials, Phase II as Topic economics, Europe, Evidence-Based Medicine, Humans, Imatinib Mesylate, Piperazines, Pyrimidines, Research Design, United Kingdom, United States, United States Food and Drug Administration, Antineoplastic Agents economics, Antineoplastic Agents pharmacology, Antineoplastic Agents standards, Drug Approval organization & administration, Drug Design
Published
2008
Full Text
View/download PDF

9. Standardization, more funds on horizon for clinical trials.

Author

McNeil C

Subjects
Clinical Trials, Phase I as Topic economics, Clinical Trials, Phase I as Topic standards, Clinical Trials, Phase II as Topic economics, Clinical Trials, Phase II as Topic standards, Clinical Trials, Phase III as Topic economics, Clinical Trials, Phase III as Topic standards, Humans, National Institutes of Health (U.S.), United States, Clinical Trials as Topic economics, Clinical Trials as Topic standards, Research Support as Topic
Published
2005
Full Text
View/download PDF

11. Financing gene therapy beyond phase II.

Author

Michael A

Subjects
Biotechnology economics, Clinical Protocols, Financing, Organized, Investments, Clinical Trials, Phase II as Topic economics, Clinical Trials, Phase III as Topic economics, Genetic Therapy economics, Research Support as Topic
Abstract

If all the gene therapy protocols now in development reach the market, not only will it be a miracle, it will also cost an estimated $37.5 billion. There are around 250 protocols currently in development, most of which are in their earliest phases. Each of them could cost between $100 million and $200 million to take to market. The money raised by gene therapy companies over the 18 months up to June 1996--550 million--would fund the development of only a small handful of protocols. Where, then, will companies get the money for clinical development?

Published
1996

12. Biotech shares fall as company halts asthma drug trials.

Author

Ward M

Subjects
Cyclic Nucleotide Phosphodiesterases, Type 4, Humans, Phosphoric Diester Hydrolases, United Kingdom, 3',5'-Cyclic-AMP Phosphodiesterases, Anti-Asthmatic Agents economics, Anti-Asthmatic Agents therapeutic use, Biotechnology economics, Clinical Trials, Phase II as Topic economics, Phosphodiesterase Inhibitors economics, Phosphodiesterase Inhibitors therapeutic use
Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results